IDB 1031

Drug Profile

IDB 1031

Alternative Names: Cyrtominetin

Latest Information Update: 22 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Indena; Inverni della Beffa
  • Class Anti-inflammatories; Expectorants; Small molecules
  • Mechanism of Action Free radical scavengers; Lipid peroxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Respiratory tract disorders

Most Recent Events

  • 30 Aug 1999 Synthélabo and Sanofi have merged to form Sanofi-Synthélabo
  • 09 Sep 1996 Inverni della Beffa is developing IDB 1031 in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top